THE LATEST FIGURES ON THE SWISS LIFE SCIENCES & BIOTECHNOLOGY INDUSTRY

BROUGHT TO YOU BY C5 COMMUNICATIONS AND BIOTECHGATE

SOURCE: biotechgate.com

The “Swiss Life Sciences Trend Analysis” is based ondata entered in the Biotechgate Databaseavailable at www.biotechgate.com.

The statistics and graphs in this presentation arebased on figures and information entered in thisdatabase and we do not guarantee anyaccuracy hereof.

Switzerland holds only 0.1% of the world’s population, but it remains a leader in wealth,

exports and life sciences.

As a smaller country, Switzerland frequently looks beyond its borders, building strong

international relationships and focusing heavily on exports.

Currently its largest export sector is chemical, pharmaceuticals and biotech, accounting for

41% of total Swiss exports.

Switzerland also houses several large multinational corporations, such as Nestle, Novartis

and Sygenta, who use the region as a hub for their global networks of R&D collaborations

and manufacturing.

The Swiss growth strategy is largely underpinned by an emphasis on constant innovation

and internationalism. A key focus is given to collaboration with foreign researchers and

also to facilitating growth in developing and transitioning countries.

Content

Overview of the Swiss Industry 4

Life Sciences & Biotechnology Industry - Overview 5

Life Sciences & Biotechnology Industry - Number of Employees 6

Life Sciences & Biotechnology Industry - Company Ownership 7

Biotech Companies - Foundation Timeline 8

Biotechnology Companies -Key Activities 9

Biotech products - Breakdown by Indication 10

Biotech products - Pipeline 11

Biotechnology Financing in Switzerland – 5 year report 12

Major Biotech Venture Financing Rounds in 2016 13

2017 Statistics

Total Biotech companies 430

Biotech – Therapeutics and Diagnostics 144

Biotech – R&D Services 208

Biotech - Other 78

Percentage of SMEs 78%

Percentage of publicly owned companies 2%

Biotech venture financing 2015/2016USD 409m /

USD 370m

Licensing opportunities 79

Life Science Industry Biotechnology Industry

April 2017 StatisticsTotal Biotech Companies 430

Medtech companies 232

Pharma companies 70

Investor companies 44

Public / Non-Profit Organizations / Medical Facilities 211

Other life science related companies 1060

Percentage of Publicly Owned Companies 1.8%

Biotech Venture financing 2015 / 2016USD 409m / USD

370m

Life Sciences Venture Financing 2015 / 2016USD 782m / USD

458m

Number of Technologies 201

Licensing Opportunities 92

11-50

28.0%

51-200

22.0%

1-10

33.3%

>200

16.7%

LIFE SCIENCES11-50

30.3%

51-200

23.6%

1-10

34.8%

>200

11.2%

BIOTECH

Private /

independent

80.1%

Subsidiary

16.2%

Publicly listed on stock exchange

3.7%

Private /

independent

81.4%

Subsidiary

16.9%

Publicly listed on stock exchange

1.8%

LIFE SCIENCES BIOTECH

0

5

10

15

20

25

30

Biotechnology - other Biotechnology - Therapeutics and Diagnostics Biotechnology / R&D Services

Biotechnology Companies - Key Activities

AgroBio

1.8%

Bioinformatics and

Bioelectronics

5.8% Contract Research and

Manufacturing

11.1%

Cosmetics

4.5%

Diagnostics and

Analytical Services

17.8%

Drug Delivery

2.7%

Environment

0.7%Food and Nutraceuticals

4.2%

Genomics and Proteomics

5.5%

Industrial Biotechnology

0.9%

Other Services and

Suppliers

22.2%

Therapeutics

20.7%

Veterinary

1.9%

Biotech products - Pipeline

0 20 40 60 80 100 120 140

Phase III

Phase II

Phase I

Preclinical

22

63

55

138

NUMBER OF BIOTECH PRODUCTS IN DEVELOPMENT

Biotechnology Financing – 5 year report

2012 H1 2012 H2 2013 H1 2013 H2 2014 H1 2014 H2 2015 H1 2015 H2 2016 H1 2016 H2

Financing Value 62.1 55.9 115.0 154.8 266.8 93.8 136.6 272.6 225.9 143.9

Count of Rounds 4 5 11 14 16 7 12 14 16 6

0

2

4

6

8

10

12

14

16

18

0.0

50.0

100.0

150.0

200.0

250.0

300.0

Fin

an

cin

g V

alu

e (

Mill

ion

USD

)

Financing Value

Count of Rounds

Download the DRAFT AGENDA by clicking here!

Book your place TODAY at the cheapest price!